217 related articles for article (PubMed ID: 22450349)
21. Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response.
Strowd RE; Salvatori R; Laterra JJ
J Oncol Pharm Pract; 2016 Jun; 22(3):517-22. PubMed ID: 25616657
[TBL] [Abstract][Full Text] [Related]
22. [Predictive value of the Knosp classification in grading the surgical resection of invasive pituitary macroadenomas. A prospective study of 23 cases].
Enseñat J; Ortega A; Topcewski T; Vilalta J; Obiols G; Mesa J; Sahuquillo J
Neurocirugia (Astur); 2006 Dec; 17(6):519-26. PubMed ID: 17242839
[TBL] [Abstract][Full Text] [Related]
23. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
Raverot G; Sturm N; de Fraipont F; Muller M; Salenave S; Caron P; Chabre O; Chanson P; Cortet-Rudelli C; Assaker R; Dufour H; Gaillard S; François P; Jouanneau E; Passagia JG; Bernier M; Cornélius A; Figarella-Branger D; Trouillas J; Borson-Chazot F; Brue T
J Clin Endocrinol Metab; 2010 Oct; 95(10):4592-9. PubMed ID: 20660056
[TBL] [Abstract][Full Text] [Related]
24. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
Murakami M; Mizutani A; Asano S; Katakami H; Ozawa Y; Yamazaki K; Ishida Y; Takano K; Okinaga H; Matsuno A
Neurosurgery; 2011 Jun; 68(6):E1761-7; discussion E1767. PubMed ID: 21389894
[TBL] [Abstract][Full Text] [Related]
25. Invasive, atypical and aggressive pituitary adenomas and carcinomas.
Sav A; Rotondo F; Syro LV; Di Ieva A; Cusimano MD; Kovacs K
Endocrinol Metab Clin North Am; 2015 Mar; 44(1):99-104. PubMed ID: 25732646
[TBL] [Abstract][Full Text] [Related]
26. Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.
Zhao Y; Xiao Z; Chen W; Yang J; Li T; Fan B
Mol Med Rep; 2015 Aug; 12(2):2313-22. PubMed ID: 25937029
[TBL] [Abstract][Full Text] [Related]
27. The role of temozolomide in the treatment of aggressive pituitary tumors.
Liu JK; Patel J; Eloy JA
J Clin Neurosci; 2015 Jun; 22(6):923-9. PubMed ID: 25772801
[TBL] [Abstract][Full Text] [Related]
28. Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature.
Lizzul L; Lombardi G; Barbot M; Ceccato F; Gardiman MP; Regazzo D; Bellu L; Mazza E; Losa M; Scaroni C
Pituitary; 2020 Aug; 23(4):359-366. PubMed ID: 32232709
[TBL] [Abstract][Full Text] [Related]
29. Anti-VEGF therapy in pituitary carcinoma.
Ortiz LD; Syro LV; Scheithauer BW; Ersen A; Uribe H; Fadul CE; Rotondo F; Horvath E; Kovacs K
Pituitary; 2012 Sep; 15(3):445-9. PubMed ID: 21918831
[TBL] [Abstract][Full Text] [Related]
30. Comment on "Non-surgical treatment of hormone-secreting pituitary tumors".
Dobson M; Del Porto L; Maartens NF
J Clin Neurosci; 2010 Sep; 17(9):1220-1. PubMed ID: 20570519
[No Abstract] [Full Text] [Related]
31. Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review.
Curtò L; Torre ML; Ferraù F; Pitini V; Altavilla G; Granata F; Longo M; Hofland LJ; Trimarchi F; Cannavò S
ScientificWorldJournal; 2010 Nov; 10():2132-8. PubMed ID: 21057727
[TBL] [Abstract][Full Text] [Related]
32. Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm.
Syro LV; Uribe H; Penagos LC; Ortiz LD; Fadul CE; Horvath E; Kovacs K
Clin Endocrinol (Oxf); 2006 Oct; 65(4):552-3. PubMed ID: 16984254
[No Abstract] [Full Text] [Related]
33. Prognostic indicators in an aggressive pituitary Crooke's cell adenoma.
Kovacs K; Diep CC; Horvath E; Cusimano M; Smyth H; Lombardero CC; Scheithauer BW; Lloyd RV
Can J Neurol Sci; 2005 Nov; 32(4):540-5. PubMed ID: 16408589
[TBL] [Abstract][Full Text] [Related]
34. Authors' Reply to "Pituitary Atypical Adenoma or Carcinoma Sensitive to Temozolomide Combined with Radiation Therapy: A Case Report of Early Identification and Management".
Curtò L; Trimarchi F
Turk Neurosurg; 2015; 25(4):679-80. PubMed ID: 26242353
[No Abstract] [Full Text] [Related]
35. Treatment of pituitary carcinomas and atypical pituitary adenomas: a review.
Hirohata T; Ishii Y; Matsuno A
Neurol Med Chir (Tokyo); 2014; 54(12):966-73. PubMed ID: 25446382
[TBL] [Abstract][Full Text] [Related]
36. Temozolomide and pituitary adenoma.
Hueng DY; Ma HI; Sytwu HK; Liu MY
J Neurosurg; 2011 Jun; 114(6):1820: author reply 1820-1. PubMed ID: 21513431
[No Abstract] [Full Text] [Related]
37. O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment?
Widhalm G; Wolfsberger S; Preusser M; Woehrer A; Kotter MR; Czech T; Marosi C; Knosp E
Cancer; 2009 Mar; 115(5):1070-80. PubMed ID: 19156926
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
Dai C; Zhang B; Liu X; Ma S; Yang Y; Yao Y; Feng M; Bao X; Li G; Wang J; Guo K; Ma W; Xing B; Lian W; Xiao J; Cai F; Zhang H; Wang R
Endocrinology; 2013 Mar; 154(3):1247-59. PubMed ID: 23384836
[TBL] [Abstract][Full Text] [Related]
39. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
McCormack AI; Wass JA; Grossman AB
Eur J Clin Invest; 2011 Oct; 41(10):1133-48. PubMed ID: 21496012
[TBL] [Abstract][Full Text] [Related]
40. Clinical Impact of the Current WHO Classification of Pituitary Adenomas.
Saeger W; Honegger J; Theodoropoulou M; Knappe UJ; Schöfl C; Petersenn S; Buslei R
Endocr Pathol; 2016 Jun; 27(2):104-14. PubMed ID: 26860936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]